<?xml version="1.0" encoding="UTF-8"?><!-- This information is licensed under the Queen's Printer License of British Columbia found: www.bclaws.ca/standards/2014/QP-License_1.0.html. Please review the license terms carefully. --><reg_pit xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:reg="http://www.gov.bc.ca/2013/legislation/regulation" xmlns:bcl="http://www.gov.bc.ca/2013/bclegislation" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:in="http://www.qp.gov.bc.ca/2013/inline" xmlns:fun="http://www.bclaws.ca/xslt/functions" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" id="9_98_pit" xsi:noNamespaceSchemaLocation="https://styles.qp.gov.bc.ca/media/REGS-PIT-XSD.xsd">
  <acttitle>Pharmacy Operations and Drug Scheduling Act</acttitle>
  <title>Drug Schedules Regulation</title>
  <regnum>9/98</regnum>
  <change section="1">
    <changenote eff="June 19, 2023">Section 1 (2) BEFORE amended by BC Reg <amendingreg>151/2023</amendingreg>, effective June 19, 2023.</changenote>
    <bcl:subsection id="d2e108">
      <bcl:num>2</bcl:num>
      <bcl:text>Each entry is preceded by a code noted as 1, 1A, 2, 3 or 4, in which</bcl:text>
      <oasis:table style="3">
        <oasis:tgroup cols="4">
          <oasis:tbody>
            <oasis:trow>
              <oasis:entry colname="c1" width="120" rowspan="5">
                <oasis:line/>
              </oasis:entry>
              <oasis:entry colname="c2" align="right">
                <oasis:line>1</oasis:line>
              </oasis:entry>
              <oasis:entry colname="c3">
                <oasis:line>=</oasis:line>
              </oasis:entry>
              <oasis:entry colname="c4">
                <oasis:line>Schedule I</oasis:line>
              </oasis:entry>
            </oasis:trow>
            <oasis:trow>
              <oasis:entry colname="c2" align="right">
                <oasis:line>1A</oasis:line>
              </oasis:entry>
              <oasis:entry colname="c3">
                <oasis:line>=</oasis:line>
              </oasis:entry>
              <oasis:entry colname="c4">
                <oasis:line>Triplicate/Duplicate Prescription Program</oasis:line>
              </oasis:entry>
            </oasis:trow>
            <oasis:trow>
              <oasis:entry colname="c2" align="right">
                <oasis:line>2</oasis:line>
              </oasis:entry>
              <oasis:entry colname="c3">
                <oasis:line>=</oasis:line>
              </oasis:entry>
              <oasis:entry colname="c4">
                <oasis:line>Schedule II</oasis:line>
              </oasis:entry>
            </oasis:trow>
            <oasis:trow>
              <oasis:entry colname="c2" align="right">
                <oasis:line>3</oasis:line>
              </oasis:entry>
              <oasis:entry colname="c3">
                <oasis:line>=</oasis:line>
              </oasis:entry>
              <oasis:entry colname="c4">
                <oasis:line>Schedule III</oasis:line>
              </oasis:entry>
            </oasis:trow>
            <oasis:trow>
              <oasis:entry colname="c2" align="right">
                <oasis:line>4</oasis:line>
              </oasis:entry>
              <oasis:entry colname="c3">
                <oasis:line>=</oasis:line>
              </oasis:entry>
              <oasis:entry colname="c4">
                <oasis:line>Schedule IV.</oasis:line>
              </oasis:entry>
            </oasis:trow>
          </oasis:tbody>
        </oasis:tgroup>
      </oasis:table>
    </bcl:subsection>
  </change>
  <change section="2">
    <changenote eff="November 23, 2021">Section 2 (3), Schedule IA BEFORE amended by BC Reg <amendingreg>292/2021</amendingreg>, effective November 23, 2021.</changenote>
    <bcl:paragraph id="d1e267">
      <bcl:text>
        <in:strong>Schedule IA</in:strong> (Triplicate/Duplicate Prescription Program): Drugs which may be sold by a pharmacist to a practitioner or on the prescription of a practitioner in accordance with Bylaw 5 (31) (6) of the bylaws to the <in:doc>Pharmacists, Pharmacy Operations and Drug Scheduling Act</in:doc>.</bcl:text>
    </bcl:paragraph>
  </change>
  <change>
    <changenote eff="June 19, 2023">Section 2 (1) and (3) (part) BEFORE amended by BC Reg <amendingreg>151/2023</amendingreg>, effective June 19, 2023.</changenote>
    <bcl:subsection id="d2e184">
      <bcl:num>1</bcl:num>
      <bcl:text>Drugs listed in Schedules I, IA, II, III and IV must be sold from licensed pharmacies.</bcl:text>
    </bcl:subsection>
    <bcl:subsection id="d2e202">
      <bcl:num>3</bcl:num>
        <bcl:text><in:strong>Schedule IV</in:strong> (Prescription by Pharmacist): Drugs which may be prescribed by a pharmacist in accordance with guidelines approved by the Council.</bcl:text>
    </bcl:subsection>
  </change>
  <change schedule="">
    <changenote eff="November 30, 2009">Schedule, item "Naproxen and its salts" was struck out by BC Reg <amendingreg>286/2009</amendingreg>, effective November 30, 2009.</changenote>
    <changenote eff="November 30, 2009">Schedule, the following items were added by BC Reg <amendingreg>286/2009</amendingreg>, effective November 30, 2009.</changenote>
    <table id="3">
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Acamprosate and its salts</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Aliskiren and its salts</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Anidulafungin</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Aprepitant and its derivatives</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Daptomycin</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Dasatanib</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Deferasirox</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Duloxetine and its salts</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Inhaled human insulin</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Lanreotide and its salts</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Lenalidomide</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Lumiracoxib</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Maraviroc</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Micafungin and its salts</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Naproxen and its salts (except when sold for oral use with a daily dosage of 440 mg)</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">2</tablecol>
        <tablecol valign="top">Naproxen sodium 220 mg per tablet (when sold in products labeled with a recommended maximum daily dose of 440 mg, and in package sizes exceeding 6 600 mg)</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">3</tablecol>
        <tablecol valign="top">Naproxen sodium 220 mg per tablet (when sold in products labeled with a recommended maximum daily dose of 440 mg, and in package sizes of up to 6 600 mg)</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Nicotinic acid when sold in (a) a modified-release oral dosage form that provides 500 mg or more per dosage unit or per daily dose, or (b) an immediate-release oral dosage form that provides more than 500 mg per dosage unit or per daily dose</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Oxaliplatin</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Paliperidone and its salts and derivatives</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Pimobendan</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Pirlimycin and its salts</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Posaconazole</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Raltegravir and its salts</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Ranibizumab</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Sitaxentan and its salts</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Telbivudine</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Varenicline and its salts</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Ziprasidone and its salts</tablecol>
      </tablerow>
    </table>
  </change>
  <change>
    <changenote eff="January 13, 2011">Schedule, items BEFORE struck out by BC Reg <amendingreg>2/2011</amendingreg>, effective January 13, 2011.</changenote>
    <table id="3">
      <tablerow>
        <tablecol align="right" valign="top">3</tablecol>
        <tablecol valign="top">Diclofenac diethylamine (in preparations for topical use on the skin in concentrations of not more than 1% diclofenac)</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">3</tablecol>
        <tablecol valign="top">Diphenhydramine and its salts and preparations (except for parenteral use or for topical use in concentrations of greater than 2%)</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Fluconazole</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Naltrexone and its salts</tablecol>
      </tablerow>
    </table>
    <changenote eff="January 13, 2011">Schedule, the following items were added by BC Reg <amendingreg>2/2011</amendingreg>, effective January 13, 2011.</changenote>
    <table id="3">
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Ambrisentan</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Dabigatran and its salts and derivatives</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">3</tablecol>
        <tablecol valign="top">Diphenhydramine and its salts and preparations (except for parenteral use or for topical use in concentrations of 2% or less when sold in containers of 300 mg or less of diphenhydramine hydrochloride)</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Etravirine and its salts</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Fluconazole (except when sold in a concentration of 150 mg per oral dosage unit as a single dose treatment and indicated for the treatment of vaginal candidiasis)</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">3</tablecol>
        <tablecol valign="top">Fluconazole (when sold in a concentration of 150 mg per oral dosage unit and indicated for the treatment of vaginal candidiasis, in package sizes containing no more than 150 mg of fluconazole)</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Methoxy polyethylene glycol-epoetin beta</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Naltrexone and its salts and derivatives</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Nelarabine</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Nepafenac</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Nilotinib and its salts</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Panitumumab</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Retapamulin</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Rivaroxaban</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Sitagliptin and its salts</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">2</tablecol>
        <tablecol valign="top">Sodium picosulphate for oral purgatives, 10 mg per pack (when found in preparations with magnesium oxide 3.5 g and citric acid 12 g)</tablecol>
      </tablerow>
    </table>
  </change>
  <change>
    <changenote eff="March 31, 2011">Schedule, item 3 Naproxen sodium 220 mg per tablet (when sold in products labeled with a recommended maximum daily dose of 440 mg, and in package sizes of up to 6 600 mg) was struck out by BC Reg <amendingreg>64/2011</amendingreg>, effective March 31, 2011.</changenote>
  </change>
  <change>
    <changenote eff="October 31, 2011">Schedule, item 1A Tapentadol was added by BC Reg <amendingreg>189/2011</amendingreg>, effective October 31, 2011.</changenote>
    <changenote>Schedule, items BEFORE deleted by BC Reg <amendingreg>190/2011</amendingreg>, effective October 31, 2011.</changenote>
    <table id="3">
      <tablerow>
        <tablecol align="right" valign="top">2</tablecol>
        <tablecol valign="top">Naproxen sodium 220 mg per tablet (when sold in products labeled with a recommended maximum daily dose of 440 mg, and in package sizes exceeding 6 600 mg)</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">2</tablecol>
        <tablecol valign="top">Niacin (in extended-release formulations)</tablecol>
      </tablerow>
    </table>
    <changenote>Schedule, items 1 Eculizumab, 1 Golimumab, 1 Lapatinib and its salts, 3 Naproxen sodium 220 mg per oral dosage unit (when sold in products labeled with a recommended maximum daily dose of 440 mg, and in package sizes exceeding 6 600 mg), 1 Olmesartan and its salts and derivatives, 1 Romiplostim, 1 Ustekinumab, and 1 Vorinostat were added by BC Reg <amendingreg>190/2011</amendingreg>, effective October 31, 2011.</changenote>
  </change>
  <change>
    <changenote eff="June 26, 2012">Schedule, items BEFORE struck out by BC Reg <amendingreg>192/2012</amendingreg>, effective June 26,2012.</changenote>
    <table id="3">
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Apiol, oil of (parsley oil)</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Centella asiatica extract and active principles thereof<footnoteref>v</footnoteref></tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Deanol and its salts and derivatives</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Dimethyl sulfoxide</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Dopamine and its salts</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Gold and its salts</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Ibuprofen and its salts (when sold in strengths greater than 400 mg per solid dosage form or per 5 mL liquid dosage form)</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Levocarnitine and its salts and derivatives</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">L-Tryptophan, when sold as a single ingredient</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Theobromine and its salts</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Uracil and its salts</tablecol>
      </tablerow>
    </table>
    <changenote eff="June 26, 2012">Schedule, the following items were added by BC Reg <amendingreg>192/2012</amendingreg>, effective June 26,2012.</changenote>
    <table id="3">
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Dimethyl sulfoxide, for veterinary use or when sold for the treatment of interstitial cystitis or scleroderma in humans</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Dopamine and its salts, when sold for administration by injection</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Dutasteride</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Gold and its salts and derivatives, when sold for administration by injection</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Ibuprofen and its salts except when sold for oral administration in a concentration of 400 mg or less per dosage unit</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">3</tablecol>
        <tablecol valign="top">Ibuprofen and its salts containing 400 mg or less per oral dosage unit (when sold in package sizes exceeding 18 000 mg)</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Levocarnitine and its salts and derivatives, when sold for the treatment of primary or secondary levocarnitine deficiency</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">L-Tryptophan, when sold<br/> (a) for human use in oral dosage form at a concentration of more than 220 mg per dosage unit or per daily dose, as a single ingredient or in combination with other ingredients, or<br/> (b) for human or veterinary use as a single ingredient intended for any route of administration other than oral</tablecol>
      </tablerow>
      <tablerow>
        <tablecol align="right" valign="top">1</tablecol>
        <tablecol valign="top">Uracil and its salts, when sold for the treatment of cancer</tablecol>
      </tablerow>
    </table>
  </change>
  <change>
    <changenote eff="September 28, 2015">Schedule, items BEFORE struck out by BC Reg <amendingreg>180/2015(a)</amendingreg>, effective September 28, 2015.</changenote>
    <oasis:table style="3">
      <oasis:tgroup cols="2">
        <oasis:colspec colname="c1" colnum="1"/>
        <oasis:colspec colname="c2" colnum="2"/>
        <oasis:tbody>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Bisacodyl and its salts</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Diclofenac and its salts, except when sold as a single medicinal ingredient in a concentration equivalent of 1% or less diclofenac in preparations for topical use on the skin</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Minoxidil (except in topical solution in concentrations of 2% or less)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Minoxidil topical solution in concentrations of 2% or less</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Omeprazole and its salts</oasis:line>
            </oasis:entry>
          </oasis:trow>
        </oasis:tbody>
      </oasis:tgroup>
    </oasis:table>
    <changenote eff="September 28, 2015">Schedule, the following items were added by BC Reg <amendingreg>180/2015(b)</amendingreg>, effective September 28, 2015.</changenote>
    <oasis:table style="3">
      <oasis:tgroup cols="2">
        <oasis:colspec colname="c1" colnum="1"/>
        <oasis:colspec colname="c2" colnum="2"/>
        <oasis:tbody>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Bisacodyl and its salts except when sold in<in:br/> (a) concentrations of 5 mg or less per oral dosage unit or 10 mg or less per rectal dosage unit/suppository, and<in:br/> (b) package sizes containing no more than 50 mg of bisacodyl</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Diclofenac and its salts, including but not limited to diclofenac diethylamine, diclofenac sodium and diclofenac potassium, except when sold as a single medicinal ingredient for topical use on the skin in a concentration equivalent to 2% or less of diclofenac for not more than 7 days</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Diclofenac diethylamine when sold as a single medicinal ingredient for topical use on the skin for not more than 7 days,<in:br/> (a) in concentrations greater than 1.16% and less than or equal to 2.32%, and<in:br/> (b) in package sizes containing greater than 2.6 g of diclofenac diethylamine</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Diclofenac diethylamine when sold as a single medicinal ingredient for topical use on the skin for not more than 7 days,<in:br/> (a) in concentrations greater than 1.16% and less than or equal to 2.32%, and<in:br/> (b) in package sizes containing no more than 2.6 g of diclofenac diethylamine</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Dimeticone 100 cSt solution 50% w/w for topical use in the treatment of head lice</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Minoxidil except when sold in preparations for topical use in concentrations of 5% or less</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Minoxidil foam for topical use in concentrations of 5% or less for androgenetic alopecia (male or female pattern baldness or hair loss)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Minoxidil in solutions for topical use in concentrations of 2% or less</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Omeprazole or its salts except when sold for the 14-day treatment for frequent heartburn at a daily dose of 20mg in package sizes of no more than 280mg of omeprazole</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Omeprazole or its salts when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg in package sizes of no more than 280 mg of omeprazole</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Pancreatic extracts when sold in a dosage form that provides more than 20 000 USP units of lipase activity per dosage unit or indicated for the treatment of pancreatic exocrine insufficiency</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Pancreatin when sold in a dosage form that provides more than 20 000 USP units of lipase activity per dosage unit or indicated for the treatment of pancreatic exocrine insufficiency</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Pancrelipase when sold in a dosage form that provides more than 20 000 USP units of lipase activity per dosage unit or indicated for the treatment of pancreatic exocrine insufficiency</oasis:line>
            </oasis:entry>
          </oasis:trow>
        </oasis:tbody>
      </oasis:tgroup>
    </oasis:table>
    <changenote eff="September 28, 2015">Schedule, items BEFORE struck out by BC Reg <amendingreg>181/2015(a)</amendingreg>, effective September 28, 2015.</changenote>
    <oasis:table style="3">
      <oasis:tgroup cols="2">
        <oasis:colspec colname="c1" colnum="1"/>
        <oasis:colspec colname="c2" colnum="2"/>
        <oasis:tbody>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Acyclovir and its salts (in topical preparations in concentrations of 5% or less)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Acyclovir and its salts (except in topical preparations in concentrations of 5% or less)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Adrenocortical hormones and their salts and derivatives<in:footnoteref>V</in:footnoteref> (except<in:br/> (a) hydrocortisone or hydrocortisone acetate, when sold as a single medicinal ingredient in a concentration that provides 0.5% or less hydrocortisone in preparations for topical use on the skin, and<in:br/> (b) clobetasone butyrate, when sold in a concentration of 0.05% clobetasone butyrate in cream preparations for topical use on the skin)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Azelaic acid</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Hydrocortisone<in:footnoteref>V</in:footnoteref> (except when sold as a single medicinal ingredient in a concentration that provides 0.5% hydrocortisone in preparations for topical use on the skin)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Hydrocortisone (when sold as a single medicinal ingredient in a concentration that provides 0.5% hydrocortisone in preparations for topical use on the skin)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Hydrocortisone acetate<in:footnoteref>V</in:footnoteref> (except when sold as a single medicinal ingredient in a concentration that provides 0.5% hydrocortisone in preparations for topical use on the skin)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Hydrocortisone acetate (when sold as a single medicinal ingredient in a concentration that provides 0.5% hydrocortisone in preparations for topical use on the skin)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Naproxen and its salts (except when sold for oral use with a daily dosage of 440 mg)</oasis:line>
            </oasis:entry>
          </oasis:trow>
        </oasis:tbody>
      </oasis:tgroup>
    </oasis:table>
    <changenote eff="September 28, 2015">Schedule, the following items were added by BC Reg <amendingreg>181/2015(b)</amendingreg>, effective September 28, 2015.</changenote>
    <oasis:table style="3">
      <oasis:tgroup cols="2">
        <oasis:colspec colname="c1" colnum="1"/>
        <oasis:colspec colname="c2" colnum="2"/>
        <oasis:tbody>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Acyclovir and its salts</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Adrenocortical hormones and their salts and derivatives<in:footnoteref>v</in:footnoteref>, including, but not limited to, hydrocortisone, hydrocortisone acetate, hydrocortisone valerate, hydrocortisone sodium succinate, clobetasone butyrate, difluprednate and triamcinolone acetonide (except<in:br/> (a) hydrocortisone or hydrocortisone acetate, when sold as a single medicinal ingredient in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin,<in:br/> (b) hydrocortisone or hydrocortisone acetate, when sold in combination with any other non-prescription medicinal ingredient that provides 1% or less hydrocortisone in preparations for topical use on the skin,<in:br/>(c) clobetasone butyrate, when sold in a concentration of 0.05% clobetasone butyrate in cream preparations for topical use on the skin, and<in:br/> (d) triamcinolone acetonide in an aqueous nasal spray that delivers 55 mcg per metered spray for adults and children 12 years of age and older)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Azelaic acid</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Hydrocortisone or hydrocortisone acetate<in:footnoteref>v</in:footnoteref> (except when sold in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin, for adults and children 2 years of age and over, and in package sizes containing no more than 30 g)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Hydrocortisone or hydrocortisone acetate (when sold in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin, for adults and children 2 years of age and over, and in package sizes containing no more than 30 g)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Naproxen and its salts (except when sold as naproxen sodium 220 mg per oral dosage unit)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Triamcinolone acetonide in an aqueous nasal spray that delivers 55 mcg per metered spray for adults and children 12 years of age and older, in package sizes containing more than 120 metered sprays</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Triamcinolone acetonide in an aqueous nasal spray that delivers 55 mcg per metered spray for adults and children 12 years of age and older, in package sizes containing no more than 120 metered sprays</oasis:line>
            </oasis:entry>
          </oasis:trow>
        </oasis:tbody>
      </oasis:tgroup>
    </oasis:table>
  </change>
  <change>
    <changenote eff="March 23, 2016">Schedule, duplicate item BEFORE struck out by BC Reg <amendingreg>83/2016</amendingreg>, effective March 23, 2016.</changenote>
    <oasis:table style="3">
      <oasis:tgroup cols="2">
        <oasis:tbody>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Azelaic acid</oasis:line>
            </oasis:entry>
          </oasis:trow>
        </oasis:tbody>
      </oasis:tgroup>
    </oasis:table>
    <changenote eff="March 23, 2016">Schedule, item BEFORE struck out by BC Reg <amendingreg>83/2016</amendingreg>, effective March 23, 2016.</changenote>
    <oasis:table style="3">
      <oasis:tgroup cols="2">
        <oasis:tbody>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Naloxone and its salts</oasis:line>
            </oasis:entry>
          </oasis:trow>
        </oasis:tbody>
      </oasis:tgroup>
    </oasis:table>
    <changenote eff="March 23, 2016">Schedule, items added by BC Reg <amendingreg>83/2016</amendingreg>, effective March 23, 2016.</changenote>
    <oasis:table style="3">
      <oasis:tgroup cols="2">
        <oasis:tbody>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Naloxone and its salts (except when used for opioid overdose emergencies outside hospital settings)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Naloxone and its salts when used for opioid overdose emergencies outside hospital settings</oasis:line>
            </oasis:entry>
          </oasis:trow>
        </oasis:tbody>
      </oasis:tgroup>
    </oasis:table>
  </change>
  <change>
    <changenote eff="June 24, 2016">Schedule, items added by BC Reg <amendingreg>160/2016</amendingreg>, effective June 24, 2016.</changenote>
    <oasis:table style="3">
      <oasis:tgroup cols="2">
        <oasis:tbody>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Dextroamphetamine or its salts</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Diphenoxylate or its salts</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Methylphenidate or its salts</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Phenobarbital or its salts</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Secobarbital or its salts</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Tramadol or its salts</oasis:line>
            </oasis:entry>
          </oasis:trow>
        </oasis:tbody>
      </oasis:tgroup>
    </oasis:table>
  </change>
  <change>
    <changenote eff="September 20, 2016">Schedule, item BEFORE struck out by BC Reg <amendingreg>230/2016</amendingreg>, effective September 20, 2016.</changenote>
    <oasis:table style="3">
      <oasis:tgroup cols="2">
        <oasis:tbody>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Naloxone and its salts when used for opioid overdose emergencies outside hospital settings</oasis:line>
            </oasis:entry>
          </oasis:trow>
        </oasis:tbody>
      </oasis:tgroup>
    </oasis:table>
  </change>
  <change>
    <changenote eff="December 5, 2016">Schedule, items BEFORE struck out by BC Reg <amendingreg>279/2016</amendingreg>, effective December 5, 2016.</changenote>
    <oasis:table style="3">
      <oasis:tgroup cols="2">
        <oasis:tbody>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Adrenocortical hormones and their salts and derivatives<in:footnoteref>v</in:footnoteref>, including, but not limited to, hydrocortisone, hydrocortisone acetate, hydrocortisone valerate, hydrocortisone sodium succinate, clobetasone butyrate, difluprednate and triamcinolone acetonide (except<in:br/> (a) hydrocortisone or hydrocortisone acetate, when sold as a single medicinal ingredient in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin,<in:br/> (b) hydrocortisone or hydrocortisone acetate, when sold in combination with any other non-prescription medicinal ingredient that provides 1% or less hydrocortisone in preparations for topical use on the skin,<in:br/>(c) clobetasone butyrate, when sold in a concentration of 0.05% clobetasone butyrate in cream preparations for topical use on the skin, and<in:br/> (d) triamcinolone acetonide in an aqueous nasal spray that delivers 55 mcg per metered spray for adults and children 12 years of age and older)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Esomeprazole and its salts</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Ibuprofen and its salts except when sold for oral administration in a concentration of 400 mg or less per dosage unit</oasis:line>
            </oasis:entry>
          </oasis:trow>
        </oasis:tbody>
      </oasis:tgroup>
    </oasis:table>
    <changenote eff="December 5, 2016">Schedule, items added by BC Reg <amendingreg>279/2016</amendingreg>, effective December 5, 2016.</changenote>
    <oasis:table style="3">
      <oasis:tgroup cols="2">
        <oasis:tbody>
          <oasis:trow>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Adrenocortical hormones and their salts and derivativesv, including, but not limited to, hydrocortisone, hydrocortisone acetate, hydrocortisone valerate, hydrocortisone sodium succinate, clobetasone butyrate,<in:br/> difluprednate, triamcinolone acetonide and fluticasone (except<in:br/> (a) hydrocortisone or hydrocortisone acetate, when sold as a single medicinal ingredient in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin,<in:br/> (b) hydrocortisone or hydrocortisone acetate, when sold in combination with any other non-prescription medicinal ingredient that provides 1% or less hydrocortisone in preparations for topical use on the skin,<in:br/> (c) clobetasone butyrate, when sold in a concentration of 0.05% clobetasone butyrate in cream preparations for topical use on the skin,<in:br/> (d) triamcinolone acetonide in an aqueous nasal spray that delivers 55 mcg per metered spray for adults and children 12 years of age and older, and<in:br/> (e) fluticasone propionate, when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg per metered spray for individuals 18 years of age and older)<in:br/></oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Esomeprazole and its salts except when sold for the 14-day treatment for frequent heartburn, at a daily dose of 20 mg and in package sizes of no more than 280 mg of esomeprazole</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Esomeprazole and its salts when sold for the 14-day treatment for frequent heartburn, at a daily dose of 20 mg and in package sizes of no more than 280 mg of esomeprazole</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Fluticasone propionate when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg per metered spray, for individuals 18 years of age and older and in package sizes containing more than 120 metered sprays</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Fluticasone propionate when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg per metered spray, for individuals 18 years of age and older and in package sizes containing no more than 120 metered sprays</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Ibuprofen and its salts except when sold in<in:br/> (a) an oral dosage form that provides 400 mg or less per dosage unit, or<in:br/> (b) a modified-release oral dosage form that provides 600 mg or less per dosage unit</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Ibuprofen and its salts when sold in a modified-release oral dosage form that provides 600 mg or less per dosage unit.</oasis:line>
            </oasis:entry>
          </oasis:trow>
        </oasis:tbody>
      </oasis:tgroup>
    </oasis:table>
  </change>
  <change>
    <changenote eff="January 27, 2017">Schedule, item BEFORE amended by BC Reg <amendingreg>6/2017</amendingreg>, effective January 27, 2017.</changenote>
    <oasis:table style="3">
      <oasis:tgroup cols="2">
        <oasis:colspec colname="c1" colnum="1"/>
        <oasis:colspec colname="c2" colnum="2"/>
        <oasis:tbody>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Naloxone and its salts (except when used for opioid overdose emergencies outside hospital settings)</oasis:line>
            </oasis:entry>
          </oasis:trow>
        </oasis:tbody>
      </oasis:tgroup>
    </oasis:table>
  </change>
  <change>
    <changenote eff="June 28, 2018">Schedule, items BEFORE struck out by BC Reg <amendingreg>137/2018</amendingreg>, effective June 28, 2018.</changenote>
    <oasis:table style="3">
      <oasis:tgroup cols="2">
        <oasis:tbody>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Adenosine and its salts (for parenteral use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c2" valign="top" align="right">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Adrenocortical hormones and their salts and derivatives<in:footnoteref>V</in:footnoteref>, including, but not limited to, hydrocortisone, hydrocortisone acetate, hydrocortisone valerate, hydrocortisone sodium succinate, clobetasone butyrate, difluprednate, triamcinolone acetonide and fluticasone (except<in:br/> (a) hydrocortisone or hydrocortisone acetate, when sold as a single medicinal ingredient in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin,<in:br/> (b) hydrocortisone or hydrocortisone acetate, when sold in combination with any other non-prescription medicinal ingredient that provides 1% or less hydrocortisone in preparations for topical use on the skin,<in:br/> (c) clobetasone butyrate, when sold in a concentration of 0.05% clobetasone butyrate in cream preparations for topical use on the skin,<in:br/> (d) triamcinolone acetonide in an aqueous nasal spray that delivers 55 mcg per metered spray for adults and children 12 years of age and older, and<in:br/> (e) fluticasone propionate, when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg per metered spray for individuals 18 years of age and older)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Antipyrine (except preparations for topical or otic use)<in:footnoteref>V</in:footnoteref></oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Antipyrine for otic or topical use</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Apomorphine and its salts</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Cimetidine and its salts (except when sold in concentrations of 100 mg or less per unit dose)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Cimetidine and its salts when sold in concentrations of 100 mg or less per unit dose</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Deoxycholic acid and its salts</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Dimenhydrinate and its salts (for oral use when sold in packages of greater than 30 dosage units or for parenteral use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Dimenhydrinate and its salts (for oral use when sold in packages of 30 dosage units or less or for rectal use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Glycopyrrolate and its salts</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Hyoscine and its salts and derivatives [scopolamine]</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Levonorgestrel when sold in concentrations of 0.75 mg per oral dosage unit (except when labelled to be taken as a single dose of 1.5 mg and in package sizes containing no more than 1.5 mg levonorgestrel, packaged and labelled for emergency contraception)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Levonorgestrel (when sold in concentrations of 0.75 mg per oral dosage unit to be taken as a single dose of 1.5 mg, packaged and labelled for emergency contraception, in package sizes containing no more than 1.5 mg levonorgestrel)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Minoxidil foam for topical use in concentrations of 5% or less for androgenetic alopecia (male or female pattern baldness or hair loss)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Minoxidil in solutions for topical use in concentrations of 2% or less</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Phenylephrine hydrochloride for ophthalmic use in concentrations of 2.5% or less</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Potassium salts (oral preparations containing more than 5 mmol per single dose)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Salicylic acid and its salts (in topical preparations in concentrations over 40%)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Sodium chloride (single ingredient solutions in concentrations of more than 0.9%)</oasis:line>
            </oasis:entry>
          </oasis:trow>
        </oasis:tbody>
      </oasis:tgroup>
    </oasis:table>
    <changenote eff="June 28, 2018">Schedule, items added by BC Reg <amendingreg>137/2018</amendingreg>, effective June 28, 2018.</changenote>
    <oasis:table style="3">
      <oasis:tgroup cols="2">
        <oasis:tbody>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Acetaminophen, when recommended for administration by intravenous injection</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Adenosine or its salts when sold or recommended for administration by intravenous injection</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c2" valign="top" align="right">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Adrenocortical hormones and their salts and derivatives<in:footnoteref>V</in:footnoteref>, including but not limited to betamethasone dipropionate, betamethasone phosphate, betamethasone sodium, betamethasone valerate, budesonide, ciclesonide, clobetasone, cortisone, dexamethasone acetate, dexamethasone phosphate, dexamethasone sodium, difluprednate, fludrocortisone acetate, flunisolide, fluticasone furoate, fluticasone propionate, hydrocortisone aceponate, hydrocortisone acetate, hydrocortisone sodium, methylprednisolone acetate, methylprednisolone, methylprednisolone sodium, methylprednisolone succinate, mometasone furoate, prednisolone acetate, prednisolone phosphate, prednisolone sodium, prednisone, triamcinolone acetonide, triamcinolone hexacetonide (except<in:br/> (a) hydrocortisone or hydrocortisone acetate, when sold as a single medicinal ingredient in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin,<in:br/> (b) hydrocortisone or hydrocortisone acetate, when sold in combination with any other non-prescription medicinal ingredient that provides 1% or less hydrocortisone in preparations for topical use on the skin,<in:br/> (c) clobetasone butyrate, when sold in a concentration of 0.05% in cream preparations for topical use on the skin,<in:br/> (d) fluticasone propionate, when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg per metered spray for individuals 18 years of age and older),<in:br/> (e) mometasone furoate for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg per spray for those 12 years of age and older, and<in:br/> (f) triamcinolone acetonide in a nasal spray that delivers 55 mcg per spray for adults and children 12 years of age and older</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Aluminum oxide</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Amobarbital</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Amphetamine</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Anetholtrithione</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Antipyrine (except preparations for topical use)<in:footnoteref>V</in:footnoteref></oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Antipyrine (except otic preparations)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Antipyrine (for otic use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Apomorphine and its salts</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Benzphetamine</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Chlophedianol and its salts</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Cimetidine or its salts (except when sold in concentrations of 200 mg or less per oral dosage unit and indicated for the treatment of heartburn)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Cimetidine or its salts, when sold in concentrations of 100 mg or less per oral dosage unit and indicated for the treatment of heartburn</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Copper chloride (cupric chloride) in injectable form for parenteral nutrition</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Deoxycholic acid and its salts, when used in an injectable form</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Deoxycholic acid and its salts (except when used in an injectable form)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1A</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Diacetylmorphine</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Dimenhydrinate and its salts (for parenteral use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Dimenhydrinate and its salts (for oral or rectal use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Electrolyte solutions (for oral rehydration)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Ephedrine and its salts in combination products (in preparations containing no more than 8 mg per unit dose, with a label recommending no more than 8 mg/dose or 32 mg/day and for use for no more than 7 days, and indicated for nasal congestion)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Ephedrine and its salts in single entity products (in preparations containing no more than 8 mg per unit dose, with a label recommending no more than 8 mg/dose or 32 mg/day and for use for no more than 7 days, and indicated for nasal congestion)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Glycopyrrolate or its salts (except glycopyrronium bromide, including but not limited to glycopyrrolate, when used orally or for inhalation)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Glycopyrronium bromide (including but not limited to glycopyrrolate, when used orally or for inhalation)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Hyoscine and its salts and derivatives [scopolamine] (except hyoscine butylbromide, when recommended for parenteral use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Hyoscine butylbromide (when recommended for parenteral use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Ketamine and its salts</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Levonorgestrel (when sold in concentrations of 1.5 mg or less per oral dosage unit, except when labelled to be taken as a single dose of 1.5 mg and in package sizes containing no more than 1.5 mg levonorgestrel, packaged and labelled for emergency contraception)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Levonorgestrel (when sold in concentrations of 1.5 mg or less per oral dosage unit to be taken as a single dose of 1.5 mg, packaged and labelled for emergency contraception, in package sizes containing no more than 1.5 mg of levonorgestrel)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Lidocaine (when in a preparation containing an equal amount of tetracaine and recommended for topical use on the skin, in concentrations of 7% or higher)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Magnesium sulfate (for parenteral use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Methamphetamine</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Mifepristone or its derivatives</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Nicotinic acid [niacin] in extended-release formulations, except when sold in a modified-release oral dosage form that provides 500 mg or more per dosage unit or per daily dose</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Phendimetrazine and its salts</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Phenmetrazine and its salts</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Potassium citrate (when recommended for the treatment of renal tubular acidosis and kidney stones)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Potassium salts (in oral preparations containing more than 5 mmol per single dose, except<in:br/> (a) potassium bromide,<in:br/> (b) potassium gluconate when sold or recommended for administration to cats,<in:br/> (c) potassium para-aminobenzoate, and<in:br/> (d) potassium citrate when recommended for the treatment of renal tubular acidosis and kidney stones)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Pseudoephedrine and its salts and preparations in combination products</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Pseudoephedrine and its salts and preparations in single entity products</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Salicylic acid (when sold in topical formulations containing salicylic acid at concentrations greater than 20% or with a pH less than 3.0, or both, except when sold to be applied to warts, corns or calluses)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Salicylic acid (when sold to be applied to warts, corns or calluses in topical preparations in concentrations greater than 40%)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Sodium acetate (for parenteral use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Sodium chloride (single ingredient solutions for parenteral or ophthalmic use in concentrations of more than 0.9%) [NOTE: Does not apply to contact lens solutions intended to be rinsed off prior to insertion into eye]</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Sodium phosphate (for parenteral use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Tetracaine (when in a preparation containing an equal amount of lidocaine and recommended for topical use on the skin, in concentrations of 7% or higher)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Ulipristal or its salts or derivatives (including but not limited to ulipristal acetate)</oasis:line>
            </oasis:entry>
          </oasis:trow>
        </oasis:tbody>
      </oasis:tgroup>
    </oasis:table>
  </change>
  <change>
    <changenote eff="December 7, 2018">Schedule, items "Phytocnnabinoids" with description and "Synthetic cannabinoid receptor type-1 agonists" with description were added by BC Reg <amendingreg>261/2018</amendingreg>, effective December 7, 2018.</changenote>
  </change>
  <change>
    <changenote eff="January 23, 2019">Schedule, item "1 Nicotine" and description BEFORE amended by BC Reg <amendingreg>9/2019</amendingreg>, effective January 23, 2019.</changenote>
    <oasis:table style="3">
      <oasis:tgroup cols="2">
        <oasis:tbody>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Nicotine and its salts, for human use, except<in:br/> (a) in natural substances;<in:br/> (b) in the form of a chewing gum containing 4 mg or less of nicotine per dosage unit;<in:br/> (c) in the form of a transdermal patch with a delivery rate of 22 mg or less of nicotine per day;<in:br/> (d) in a form to be administered orally by means of an inhalation device delivering 4 mg or less of nicotine per dosage unit; or<in:br/> (e) in the form of a lozenge containing 4 mg or less of nicotine per dosage unit</oasis:line>
            </oasis:entry>
          </oasis:trow>
        </oasis:tbody>
      </oasis:tgroup>
    </oasis:table>
    <changenote eff="January 23, 2019">Schedule, items "1 Codeine" and "1 Lisdexamfetamine" were added by BC Reg <amendingreg>9/2019</amendingreg>, effective January 23, 2019.</changenote>
  </change>
  <change>
    <changenote eff="June 17, 2019">Schedule, item 1 and 2 "Esomeprazole and its salts" BEFORE struck out by BC Reg <amendingreg>135/2019</amendingreg>, effective June 17, 2019.</changenote>
    <oasis:table style="1">
      <oasis:tgroup cols="2">
        <oasis:tbody>
          <oasis:trow>
            <oasis:entry colname="c2" valign="top" align="right">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Esomeprazole and its salts except when sold for the 14-day treatment for frequent heartburn, at a daily dose of 20 mg and in package sizes of no more than 280 mg of esomeprazole</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c2" valign="top" align="right">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Esomeprazole and its salts when sold for the 14-day treatment for frequent heartburn, at a daily dose of 20 mg and in package sizes of no more than 280 mg of esomeprazole</oasis:line>
            </oasis:entry>
          </oasis:trow>
        </oasis:tbody>
      </oasis:tgroup>
    </oasis:table>
    <changenote eff="June 17, 2019">Schedule, items were added by BC Reg <amendingreg>135/2019</amendingreg>, effective June 17, 2019.</changenote>
    <oasis:table style="1">
      <oasis:tgroup cols="2">
        <oasis:tbody>
          <oasis:trow>
            <oasis:entry colname="c2" valign="top" align="right">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Esomeprazole or its salts for human use including but not limited to esomeprazole magnesium except when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of esomeprazole</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c2" valign="top" align="right">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Esomeprazole or its salts for human use when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of esomeprazole</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c2" valign="top" align="right">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Esomeprazole or its salts for veterinary use</oasis:line>
            </oasis:entry>
          </oasis:trow>
        </oasis:tbody>
      </oasis:tgroup>
    </oasis:table>
  </change>
  <change>
    <changenote eff="January 6, 2020">Schedule, items BEFORE struck out by BC Reg <amendingreg>1/2020</amendingreg>, effective January 6, 2020.</changenote>
    <oasis:table style="1">
      <oasis:tgroup cols="2">
        <oasis:tbody>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Codeine, except<in:br/> (a) when prescribed as a single entity,<in:br/> (b) when included in a preparation containing 60 mg or more per dosage unit, or<in:br/> (c) in preparations exempted from the Regulations to the <in:doc>Controlled Drugs and Substances Act</in:doc> (Canada) </oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1A</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Codeine when prescribed as a single entity or when included in a preparation containing 60 mg or more per dosage unit</oasis:line>
            </oasis:entry>
          </oasis:trow>
        </oasis:tbody>
      </oasis:tgroup>
    </oasis:table>
    <changenote eff="January 6, 2020">Schedule, items "1 Codeine and its salts" and "1A Codeine and its salts" were added by BC Reg <amendingreg>1/2020</amendingreg>, effective January 6, 2020.</changenote>
  </change>
  <change>
    <changenote eff="November 23, 2021">Schedule, items BEFORE struck out by BC Reg <amendingreg>292/2021</amendingreg>, effective November 23, 2021.</changenote>
    <oasis:table style="1">
      <oasis:tgroup cols="2">
        <oasis:tbody>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Aloe vera latex, its extracts and derivatives (except aloin) (dosage forms for systemic use containing more than 300 mg per dosage unit)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Aluminum oxide</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Benzocaine and its salts (for parenteral or ophthalmic use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Berberis vulgaris (Barberry)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Casanthranol</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Deoxycholic acid and its salts, when used in an injectable form</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Electrolyte solutions (for oral rehydration)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Fluoride and its salts (oral preparations containing 1 mg or less of fluoride ion per dosage unit)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c2" valign="top" align="right">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Fluticasone propionate when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg per metered spray, for individuals 18 years of age and older and in package sizes containing more than 120 metered sprays</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Heparin and its salts (for topical use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Hydrocortisone or hydrocortisone acetate (when sold in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin, for adults and children 2 years of age and over, and in package sizes containing no more than 30 g)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Hydroquinone (topical preparations)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Iodine and its salts and derivatives (for topical use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Lactic acid (preparations in concentrations of more than 10%)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Magnesium citrate (cathartics)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Magnesium salicylate (except oral dosage forms which also contain choline salicylate)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Narcotine and its salts (Noscapine)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Noscapine</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Povidone - iodine (topical preparations, except in concentrations of 5% or less)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Sodium biphosphate (cathartic)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Sodium phosphate (cathartics)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Vitamin D in oral dosage form containing more than 1 000 International Units of Vitamin D per dosage form or, where the largest recommended daily dosage shown on the label would, if consumed by a person, result in the daily intake by that person of more than 1 000 International Units of Vitamin D</oasis:line>
            </oasis:entry>
          </oasis:trow>
        </oasis:tbody>
      </oasis:tgroup>
    </oasis:table>
    <changenote eff="November 23, 2021">Schedule, the following items and descriptions "3 Acetaminophen and ibuprofen", "2 Acetaminophen and ibuprofen", "1 Alpha-hydroxy acids", "2 Fluticasone propionate", "3 Fluticasone propionate", "1 Hydroquinone or its derivatives", "2 Hydroquinone or its derivatives", "1 Mometasone furoate" and "1 Vitamin D" were added by BC Reg <amendingreg>292/2021</amendingreg>, effective November 23, 2021.</changenote>
  </change>
  <change>
    <changenote eff="April 19, 2022">Schedule, items BEFORE struck out by BC Reg <amendingreg>106/2022</amendingreg>, effective April 19, 2022.</changenote>
    <oasis:table style="1">
      <oasis:tgroup cols="2">
        <oasis:tbody>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Acetylcysteine</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Allethrins (pyrethrins)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Alverine and its salts (for parenteral use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Amino acid solutions (for parenteral use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Arginine and its salts</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Artemisia, its preparations, extracts and compounds (except in trace amounts in homeopathic preparations)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Belladonna alkaloids, and their salts and derivatives (except in preparations for topical use or in trace amounts in homeopathic preparations)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Benzocaine and its salts (for parenteral or ophthalmic use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Benzyl benzoate</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Bisacodyl and its salts except when sold in<in:br/>    (a) concentrations of 5 mg or less per oral dosage unit or 10 mg or less per rectal dosage unit/suppository, and<in:br/>    (b) package sizes containing no more than 50 mg of bisacodyl</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Boric acid and its salts (in preparations for systemic use, or ophthalmic preparations in concentrations of greater than 2%) [Note: does not apply to contact lens solutions intended to be rinsed off prior to placement of lens on the eye]</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Camphor (in oleaginous vehicles and in liquid forms in concentrations greater than 11%)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Cantharides, their preparations and derivatives</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Choline bitartrate (parenteral)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Chymopapain (parenteral)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Chymotrypsin (parenteral and ophthalmic)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Dextrose (sclerosing agents)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Epinephrine and its salts (other than in pre-filled syringes intended for emergency administration by injection in the event of anaphylactic reactions to allergens)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Esdepallethrin/piperonyl butoxide</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Heparin and its salts (except for topical use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Histamine and its salts (except for topical use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Hyaluronic acid and its salts (preparations in concentrations of 5% or more)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Hyaluronidase</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Hydrocortisone or hydrocortisone acetate<in:footnoteref>V</in:footnoteref> (except when sold in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin, for adults and children 2 years of age and over, and in package sizes containing no more than 30 g)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Hydroquinone or its derivatives, when sold in a concentration greater than 2% in preparations for topical use on the skin</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Hydroquinone or its derivatives, when sold in a concentration less than or equal to 2% in preparations for topical use on the skin</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Hyoscine and its salts and derivatives [scopolamine] (except hyoscine butylbromide, when recommended for parenteral use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Hyoscyamine and its salts and derivatives (except for topical use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Iodine and its salts and derivatives (except topical preparations or in oral doses of 1 mg or less per day)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Ipecac and its extracts and derivatives (when used as an emetic)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Iron and its salts and derivatives (preparations with more than 30 mg elemental iron per solid dosage unit or 5 mL oral liquid)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Lobelia and its alkaloids and preparations (except internal preparations containing not more than 2 mg lobeline sulphate, external preparations containing not more than the equivalent of 400 mg of crude lobelia or preparations containing 130 mg or less of lobelia inflata)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Magnesium sulfate (for parenteral use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Mannitol and its salts</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Methenamine and its salts (except for topical use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Methyl salicylate (in liquid dosage forms in concentrations greater than 30%)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Nicotinic acid [niacin] in extended-release formulations, except when sold in a modified-release oral dosage form that provides 500 mg or more per dosage unit or per daily dose</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Nicotinyl-tartrate</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Norepinephrine and its salts (levarterenol, noradrenaline)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Phenol (preparations with concentration of more than 20%)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Physostigmine salicylate (for oral or topical use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Potassium salts (in oral preparations containing more than 5 mmol per single dose, except<in:br/>    (a) potassium bromide,<in:br/>    (b) potassium gluconate when sold or recommended for administration to cats,<in:br/>    (c) potassium para-aminobenzoate, and<in:br/>    (d) potassium citrate when recommended for the treatment of renal tubular acidosis and kidney stones)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Povidone - iodine (vaginal preparations, except in concentrations of 5% or less)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Pyrethrins (allethrins)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Pyrethrins (allethrins) /piperonyl butoxide</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Quinidine salts</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Quinine salts</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Racemethionine</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Rue and its preparations and extracts</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Salicylic acid (when sold to be applied to warts, corns or calluses in topical preparations in concentrations greater than 40%)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Scopolamine and its salts (hyoscine)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Silver nitrate</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Sodium acetate (for parenteral use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Sodium biphosphate (for parenteral use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Sodium chloride (single ingredient solutions for parenteral or ophthalmic use in concentrations of more than 0.9%) [NOTE: Does not apply to contact lens solutions intended to be rinsed off prior to insertion into eye]</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Sodium citrate (for parenteral use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Sodium iodide (for sclerosing)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Sodium phosphate (for parenteral use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Stramonium and its preparations, extracts, and compounds</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Strontium and its salts (for parenteral use)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Vitamins (any parenterals not otherwise scheduled in Schedule I)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Xylose</oasis:line>
            </oasis:entry>
          </oasis:trow>
        </oasis:tbody>
      </oasis:tgroup>
    </oasis:table>
    <bcl:footnote>
      <bcl:num>V</bcl:num>
      <bcl:text>Prescription not required if sold for veterninary use, provided that the label is labelled by the manufacturer "for agricultural use only" or "for veterinary use only."</bcl:text>
    </bcl:footnote>
    <changenote eff="April 19, 2022">Schedule, items that were added by BC Reg <amendingreg>106/2022</amendingreg>, effective April 19, 2022.</changenote>
    <oasis:table style="1">
      <oasis:tgroup cols="2">
        <oasis:tbody>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Acetylcysteine in injectable form</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Allethrins</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Alverine and its salts in injectable form</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Amino acid solutions in injectable form</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Benzocaine and its salts in injectable form</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Bilastine or its salts or derivatives</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Bisacodyl and its salts (except when sold in strengths of 5 mg or less per oral dosage unit in package sizes containing no more than 105 mg of bisacodyl and except when sold in strengths of 10 mg or less per rectal dosage unit/suppository in package sizes containing no more than 50 mg of bisacodyl)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Choline bitartrate in injectable form</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Chymopapain in injectable form</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Chymotrypsin in injectable form</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Dextrose in injectable form, when used as a sclerosing agent</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Epinephrine and its salts in injectable form, except in pre-filled syringes intended for emergency administration by injection in the event of anaphylactic reactions to allergens</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Epinephrine or its salts, when sold as epinephrine topical solution for hemostasis at a concentration equal to or greater than 1 mg/ml (1:1000)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Esketamine</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Heparin and its salts in injectable form</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Hydroquinone or its derivatives, when sold in a concentration greater than 2% in preparations for topical use on the skinV</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Hyoscine butylbromide (Butylscopolamine bromide), except when recommended for injectable use</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Hyoscine (scopolamine) in injectable form</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Magnesium sulfate in injectable form</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Norepinephrine and its salts (levarterenol, noradrenaline) in injectable form</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Piperonyl butoxide</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Quinine or its salts or derivatives, except when sold in oral dosage form that provides 50 milligrams or less of quinine base per dosage unit or per daily dose</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Sodium acetate in injectable form</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Sodium biphosphate in injectable form</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Sodium chloride, single ingredient solutions for injectable use in concentrations of more than 0.9%</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Sodium citrate in injectable form</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Sodium iodide in injectable form, when used as a sclerosing agent</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Sodium phosphate in injectable form</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Strontium and its salts in injectable form</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Vitamins in injectable form, except those listed in Schedule I .</oasis:line>
            </oasis:entry>
          </oasis:trow>
        </oasis:tbody>
      </oasis:tgroup>
    </oasis:table>
  </change>
  <change>
    <changenote eff="November 23, 2022">Schedule, items BEFORE struck out by BC Reg <amendingreg>227/2022</amendingreg>, effective November 23, 2022.</changenote>
    <oasis:table style="3">
      <oasis:tgroup cols="2">
        <oasis:colspec colname="c1" colnum="1"/>
        <oasis:colspec colname="c2" colnum="2"/>
        <oasis:tbody>
    <oasis:trow>
      <oasis:entry colname="c1" align="right" valign="top">
        <oasis:line>1</oasis:line>
      </oasis:entry>
    <oasis:entry colname="c2" valign="top">
      <oasis:line>Brimonidine and its salts</oasis:line>
    </oasis:entry>
    </oasis:trow>
    <oasis:trow>
      <oasis:entry colname="c1" align="right" valign="top">
        <oasis:line>2</oasis:line>
      </oasis:entry>
      <oasis:entry colname="c2" valign="top">
        <oasis:line>Diclofenac diethylamine when sold as a single medicinal ingredient for topical use on the skin for not more than 7 days,<in:br/>    (a) in concentrations greater than 1.16% and less than or equal to 2.32%, and<in:br/>    (b) in package sizes containing greater than 2.6 g of diclofenac diethylamine</oasis:line>
      </oasis:entry>
    </oasis:trow>
    <oasis:trow>
      <oasis:entry colname="c1" align="right" valign="top">
        <oasis:line>3</oasis:line>
      </oasis:entry>
      <oasis:entry colname="c2" valign="top">
        <oasis:line>Diclofenac diethylamine when sold as a single medicinal ingredient for topical use on the skin for not more than 7 days,<in:br/>    (a) in concentrations greater than 1.16% and less than or equal to 2.32%, and<in:br/>    (b) in package sizes containing no more than 2.6 g of diclofenac diethylamine</oasis:line>
      </oasis:entry>
    </oasis:trow>
    <oasis:trow>
      <oasis:entry colname="c1" align="right" valign="top">
        <oasis:line>2</oasis:line>
      </oasis:entry>
      <oasis:entry colname="c2" valign="top">
        <oasis:line>Strontium and its salts in injectable form</oasis:line>
      </oasis:entry>
    </oasis:trow>    
        </oasis:tbody>
      </oasis:tgroup>
    </oasis:table>
  </change>
  <change>
    <changenote eff="November 23, 2022">Schedule, items added by BC Reg <amendingreg>227/2022</amendingreg>, effective November 23, 2022.</changenote>
    <oasis:table style="3">
      <oasis:tgroup cols="2">
        <oasis:tbody>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Brimonidine or its salts (except when sold as brimonidine tartrate ophthalmic solution in concentrations up to and including 0.025%, used for the relief of redness of the eye due to minor eye irritations caused by environmental allergies, dryness and fatigue for adults of 18 years and older)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Brimonidine tartrate ophthalmic solution in concentrations up to and including 0.025%, used for the relief of redness of the eye due to minor eye irritations caused by environmental allergies, dryness and fatigue for adults of 18 years and older</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Diclofenac diethylamine, for human use, when sold as a single medicinal ingredient for topical use on the skin for not more than 7 days,<in:br/>(a) in concentrations greater than 1.16% and less than or equal to 2.32%, and<in:br/> (b) in concentrations greater than 1.16% and less than or equal to 2.32%, and</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Sotrovimab</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>2</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Strontium and its salts in injectable form (except strontium bromide)</oasis:line>
            </oasis:entry>
          </oasis:trow>
        </oasis:tbody>
      </oasis:tgroup>
    </oasis:table>
  </change>
  <change>
    <changenote eff="April 18, 2023">Schedule, item added by BC Reg <amendingreg>102/2023</amendingreg>, effective April 18, 2023.</changenote>
    <oasis:table style="3">
      <oasis:tgroup cols="2">
        <oasis:tbody>
    <oasis:trow>
      <oasis:entry colname="c1" valign="top">
        <oasis:line>1</oasis:line>
      </oasis:entry>
      <oasis:entry colname="c2" valign="top">
        <oasis:line>Semaglutide</oasis:line>
      </oasis:entry>
    </oasis:trow>
        </oasis:tbody>
      </oasis:tgroup>
    </oasis:table>
  </change>
  <change>
    <changenote eff="June 19, 2023">Schedule, items BEFORE struck out by BC Reg <amendingreg>151/2023</amendingreg>, effective June 19, 2023.</changenote>
    <oasis:table style="3">
      <oasis:tgroup cols="2">
        <oasis:tbody>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Betaine and its salts when sold or recommended for the treatment of homocystinuria</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>4</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Ethinyl estradiol (when used for emergency contraception)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>4</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Norgestrel (when used for emergency contraception)</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>4</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Progestin (when used for emergency contraception)</oasis:line>
            </oasis:entry>
          </oasis:trow>
        </oasis:tbody>
      </oasis:tgroup>
    </oasis:table>
    <changenote eff="June 19, 2023">Schedule, item added by BC Reg <amendingreg>151/2023</amendingreg>, effective June 19, 2023.</changenote>
    <oasis:table style="3">
      <oasis:tgroup cols="2">
        <oasis:tbody>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Betaine and its salts when sold or recommended for the treatment of homocystinuria<in:sup>V</in:sup></oasis:line>
            </oasis:entry>
          </oasis:trow>
        </oasis:tbody>
      </oasis:tgroup>
    </oasis:table>
  </change>
  <change>
    <changenote eff="November 20, 2023">Schedule, items added by BC Reg <amendingreg>236/2023</amendingreg>, effective November 20, 2023.</changenote>
    <oasis:table style="3">
      <oasis:tgroup cols="2">
        <oasis:tbody>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Azelastine and its salts</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Bepotastine and its salts or derivatives</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Besifloxacin and its salts</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Efinaconazole</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Loratidine and its salts and preparations in products labelled for use in children aged 2 to 11 years, in package sizes containing greater than 140 mg of loratadine</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Ozenoxacin and its salts</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Rupatadine and its salts</oasis:line>
            </oasis:entry>
          </oasis:trow>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>1</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Trifarotene and its salts</oasis:line>
            </oasis:entry>
          </oasis:trow>
        </oasis:tbody>
      </oasis:tgroup>
    </oasis:table>
    <changenote eff="November 20, 2023">Schedule, item BEFORE struck out by BC Reg <amendingreg>236/2023</amendingreg>, effective November 20, 2023.</changenote>
    <oasis:table style="3">
      <oasis:tgroup cols="2">
        <oasis:tbody>
          <oasis:trow>
            <oasis:entry colname="c1" align="right" valign="top">
              <oasis:line>3</oasis:line>
            </oasis:entry>
            <oasis:entry colname="c2" valign="top">
              <oasis:line>Loratidine and its salts and preparations in products marketed for pediatric use (under 12 years of age)</oasis:line>
            </oasis:entry>
          </oasis:trow>
        </oasis:tbody>
      </oasis:tgroup>
    </oasis:table>
  </change>
</reg_pit>